Equity Details
Price & Market Data
Price: $2.50
Daily Change: -$0.05 / 2.00%
Daily Range: $2.48 - $2.60
Market Cap: $147,069,792
Daily Volume: 350,889
Performance Metrics
1 Week: 4.96%
1 Month: -8.63%
3 Months: 7.63%
6 Months: 3.25%
1 Year: 316.4%
YTD: 9.01%
About Spero Therapeutics, Inc. (SPRO)
Quick market take on Spero Therapeutics, Inc. (SPRO). Current price: 2.50, daily change: -$0.05 / 2.00%. Market cap: 147,069,792. Performance over 1-week and 1-month.
Company Details
Employees: 25
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.